FDA places vTv Therapeutics’s cadisegliatin programme on clinical hold
The clinical hold was placed following the identification of an unresolved chromatographic signal in a recent human ADME study.
29 July 2024
29 July 2024
The clinical hold was placed following the identification of an unresolved chromatographic signal in a recent human ADME study.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.